Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension

Bibliography

• Simonneau G, Robbins IM, Beghetti M, Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43-54
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Archer SL, Badesch DB, Accf/aha 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents and the American Heart Association. Circulation 2009;119:2250-94
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Barbera JA, Channick RN, Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009;54:S85-96
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Chaouat A, Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-30
   PubMed Web of Science ®Google Scholar
• Benza RL, Miller DP, Gomberg-Maitland M, Predicting survival in pulmonary arterial hypertension: Insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (reveal). Circulation 2010;122:164-72
   PubMed Web of Science ®Google Scholar
• D'Alonzo GE, Barst RJ, Ayres SM, Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-9
   PubMed Web of Science ®Google Scholar
• Shah SJ, Thenappan T, Rich S, Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension. Circulation 2008;117:2475-83
   PubMed Web of Science ®Google Scholar
• Humbert M, Morrell NW, Archer SL, Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13-24S
   PubMed Web of Science ®Google Scholar
• Newman JH, Fanburg BL, Archer SL, Pulmonary arterial hypertension: future directions: report of a national heart, lung and blood institute/office of rare diseases workshop. Circulation 2004;109:2947-52
   PubMed Web of Science ®Google Scholar
• Olschewski H, Rose F, Schermuly R, Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther 2004;102:139-53
   PubMed Web of Science ®Google Scholar
• Whittaker N, Bunting S, Salmon J, The chemical structure of prostaglandin x (prostacyclin). Prostaglandins 1976;12:915-28
   PubMedGoogle Scholar
• Moncada S, Gryglewski R, Bunting S, An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263:663-5
   PubMed Web of Science ®Google Scholar
• Gessler T, Seeger W, Schmehl T. Inhaled prostanoids in the therapy of pulmonary hypertension. J Aerosol Med Pulm Drug Deliv 2008;21:1-12
   PubMedGoogle Scholar
• Spisni E, Bartolini G, Orlandi M, Prostacyclin (pgi2) synthase is a constitutively expressed enzyme in human endothelial cells. Exp Cell Res 1995;219:507-13
   PubMed Web of Science ®Google Scholar
• Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. Am J Cardiol 1995;75:3-10A
   PubMed Web of Science ®Google Scholar
• Leigh PJ, Cramp WA, MacDermot J. Identification of the prostacyclin receptor by radiation inactivation. J Biol Chem 1984;259:12431-6
   PubMed Web of Science ®Google Scholar
• Badesch DB, Abman SH, Simonneau G, Medical therapy for pulmonary arterial hypertension: updated accp evidence-based clinical practice guidelines. Chest 2007;131:1917-28
   PubMed Web of Science ®Google Scholar
• Christman BW, McPherson CD, Newman JH, An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327:70-5
   PubMed Web of Science ®Google Scholar
• Badesch DB, McLaughlin VV, Delcroix M, Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:56-61S
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Mendoza J, Hood M, Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990;112:485-91
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, Long WA, A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension study group. N Engl J Med 1996;334:296-302
   PubMed Web of Science ®Google Scholar
• White RJ. Update on the development of oral prostacyclin analogs for the treatment of pulmonary arterial hypertension. Adv Pulm Hypertens 2009;8:32-6
   Google Scholar
• McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477-82
   PubMed Web of Science ®Google Scholar
• Kuhn KP, Byrne DW, Arbogast PG, Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003;167:580-6
   PubMed Web of Science ®Google Scholar
• Badesch DB, Tapson VF, McGoon MD, Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-34
   PubMed Web of Science ®Google Scholar
• Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999;34:1184-7
   PubMed Web of Science ®Google Scholar
• Tapson VF, Gomberg-Maitland M, McLaughlin VV, Safety and efficacy of iv treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 2006;129:683-8
   PubMed Web of Science ®Google Scholar
• Simonneau G, Barst RJ, Galie N, Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4
   PubMed Web of Science ®Google Scholar
• Barst RJ, Galie N, Naeije R, Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006;28:1195-203
   PubMed Web of Science ®Google Scholar
• Vachiery JL, Hill N, Zwicke D, Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 2002;121:1561-5
   PubMed Web of Science ®Google Scholar
• Gomberg-Maitland M, Tapson VF, Benza RL, Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 2005;172:1586-9
   PubMed Web of Science ®Google Scholar
• Rubenfire M, McLaughlin VV, Allen RP, Transition from iv epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest 2007;132:757-63
   PubMed Web of Science ®Google Scholar
• Sitbon O, Manes A, Jais X, Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. J Cardiovasc Pharmacol 2007;49:1-5
   PubMed Web of Science ®Google Scholar
• Levin Y, Frutiger K, Wessman K, A formal study of aggressive pain management and infrequent site changes to facilitate more comfortable subcutaneous treprostinil therapy. Am J Respir Crit Care Med 2011;183:A5907
   Google Scholar
• Hiremath J, Thanikachalam S, Parikh K, Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant 2010;29:137-49
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G, Galie N, Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Oudiz RJ, Frost A, Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257-63
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Leuchte H, Halank M, Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28:691-4
   PubMed Web of Science ®Google Scholar
• Voswinckel R, Enke B, Reichenberger F, Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol 2006;48:1672-81
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Olschewski H, Ghofrani HA, A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German pph study group. J Am Coll Cardiol 2000;35:176-82
   PubMed Web of Science ®Google Scholar
• Fruhwald FM, Kjellstrom B, Perthold W, Continuous hemodynamic monitoring in pulmonary hypertensive patients treated with inhaled iloprost. Chest 2003;124:351-9
   PubMed Web of Science ®Google Scholar
• Voswinckel R, Reichenberger F, Enke B, Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulm Pharmacol Ther 2008;21:824-32
   PubMed Web of Science ®Google Scholar
• Channick RN, Olschewski H, Seeger W, Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol 2006;48:1433-7
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Benza RL, Rubin LJ, Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010;55:1915-22
   PubMed Web of Science ®Google Scholar
• Voswinckel R, Reichenberger F, Gall H, Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. Pulm Pharmacol Ther 2009;22:50-6
   PubMedGoogle Scholar
• Bourge RC, Tapson VFS, Safdar Z, Safely transitioning from inhaled iloprost to inhaled treprostinil sodium – results from a multicenter open-label study in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2011;30:s71-2
   Google Scholar
• Smadja DM, Mauge L, Gaussem P, Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension. Angiogenesis 2011;14:17-27
   PubMedGoogle Scholar
• McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006;114:1417-31
   PubMed Web of Science ®Google Scholar
• White RJ, Allen R, Torres F, Sustained plasma concentrations of treprostinil following chronic dosing of oral treprostinil in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2009;179:A3360
   Web of Science ®Google Scholar
• Olschewski H, Rohde B, Behr J, Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 2003;124:1294-304
   PubMed Web of Science ®Google Scholar